Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $115,185,390 | $101,100,480 | $107,741,750 | $91,198,160 |
| - Cash | $9,991,000 | $6,085,000 | $5,412,000 | $5,338,000 |
| + Debt | $26,711,000 | $24,987,000 | $25,230,000 | $26,695,000 |
| Enterprise Value | $131,905,390 | $120,002,480 | $127,559,750 | $112,555,160 |
| Revenue | $28,754,000 | $27,116,000 | $27,281,000 | $27,305,000 |
| % Growth | 6% | -0.6% | -0.1% | – |
| Gross Profit | $22,503,000 | $20,618,000 | $21,624,000 | $20,704,000 |
| % Margin | 78.3% | 76% | 79.3% | 75.8% |
| EBITDA | $4,434,000 | $10,496,000 | $8,852,000 | $11,329,000 |
| % Margin | 15.4% | 38.7% | 32.4% | 41.5% |
| Net Income | $480,000 | $5,665,000 | $4,592,000 | $6,225,000 |
| % Margin | 1.7% | 20.9% | 16.8% | 22.8% |
| EPS Diluted | 0.38 | 4.5 | 3.64 | 4.93 |
| % Growth | -91.6% | 23.6% | -26.2% | – |
| Operating Cash Flow | $10,828,000 | $8,006,000 | $9,072,000 | $11,384,000 |
| Capital Expenditures | -$523,000 | -$585,000 | -$728,000 | -$579,000 |
| Free Cash Flow | $10,305,000 | $7,421,000 | $8,344,000 | $10,805,000 |